JAZZ News and Press, Jazz Pharmaceuticals plc From 07/07/21

Health Canada has approved Jazz Pharmaceuticals' (JAZZ) Vyxeos for the treatment of certain adult patients with acute myeloid leukemia  ((AML)).The approval allows for the treatment of newly diagnosed therapy-related AML ((t-AML)) or AML with myelodysplasia-related changes ((AML-MRC...

Health Canada Approves Vyxeos®, the First Chemotherapy Advance in over 40 years for Adults with High-risk Acute Myeloid Leukemia (AML) Canada NewsWire DUBLIN , July 7, 2021 /CNW/ - Jazz Pharmaceuticals plc (NASDAQ: JAZZ) today announced the Health Ca...

Zhanna Hapanovich/iStock via Getty Images Concerned over high premiums of targets, the large-cap pharmaceutical companies have taken a backseat in acquisitions this year as they focused on repayment of debt accumulated due to previous deals. Meanwhile, with the need to sustain the long-term g...

Horizons ETFs Rebalances Marijuana-Focused Index Etfs Canada NewsWire TORONTO , July 6, 2021 /CNW/ - Horizons ETFs Management ( Canada ) Inc. (" Horizons ETFs ") has completed the quarterly rebalances of the holdings of the Horizons Marijuana Life Scien...

Cannabis REITs are riding a seemingly never-ending 'high' since bursting onto the scene in the late 2010s, thriving in the murky and often contradictory regulatory framework of legalized marijuana. The ongoing federal prohibition - and the resulting limit on access to traditional bank...

Pornpak Khunatorn/iStock via Getty Images The FDA granted approval to Jazz Pharmaceuticals' (JAZZ) Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) as part of a chemotherapy regimen for acute lymphoblastic leukemia or lymphoblastic lymphoma. The approval is for patients one ...

Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Approval under U.S. FDA's Real-Time Oncology Review program represents an importa...

NetworkNewsWire Editorial Coverage : In May 2013, GW Pharma listed on Nasdaq, selling 3.5 million shares at $8.90 each to investors betting that GW was charting a profitable course as a biotech developing new drugs from cannabis-derived compounds. Legal cannabis was only beginning to gain...

Real Brands Inc (OTCMKTS:RLBD) snuck one under the radar late last week, but investors interested in the CBD and Cannabis space should take note.  The company filed its Form 10 with the SEC. In this case, it was a voluntary filing because the company does report having over $10 million o...

If you have $5,000 available to invest in stocks, there are some great options out there for you. The three stocks I have listed below are underrated investments and are trading at low earnings multiples -- and 2021 could be a great year for all three of them. You don't want to make the mis...